Pharmacological investigation of 'HIM-CHX': A herbal combination in the experimental muscle wasting condition.


Journal

Experimental gerontology
ISSN: 1873-6815
Titre abrégé: Exp Gerontol
Pays: England
ID NLM: 0047061

Informations de publication

Date de publication:
01 10 2019
Historique:
received: 22 03 2019
revised: 04 07 2019
accepted: 14 07 2019
pubmed: 19 7 2019
medline: 17 7 2020
entrez: 19 7 2019
Statut: ppublish

Résumé

Muscle wasting diseases are gradually increasing with the increase in global life expectancy. This study was designed to evaluate the efficacy of HIM-CHX, a herbal combination of Boswellia serrata, Cissus quadrangularis, and Withania somnifera, on Sarcopenia. The effects of HIM-CHX on parameters such as muscle mass, grip strength, motor coordination, gait, locomotor activity and endurance were measured in rats. In addition to this, inflammatory cytokines, myokine and growth hormone levels were also evaluated. In the first experiment, HIM-CHX was administered orally to rats at the dose of 125, 250, and 500 mg/kg body weight for 12 weeks. At the end of the treatment period, muscle mass, grip strength, motor coordination and proinflammatory cytokines were evaluated. In the second experiment, HIM-CHX was administered orally at a dose of 500 mg/kg body weight for 4 weeks and gait analysis, locomotor activity, endurance and endogenous antioxidant activity were evaluated. The animals treated with HIM-CHX showed a significant improvement in gastrocnemius muscle weight, carcass weight, gait, locomotor activity and endurance. HIM-CHX exerts its effect by reducing the levels of TNF-α, IL-6, and Myostatin while increasing the IGF-1 levels which are the typical biomarkers of muscle wasting. Furthermore, the study findings indicate that HIM-CHX has the potential to correct the pathophysiological changes associated with sarcopenia.

Identifiants

pubmed: 31319130
pii: S0531-5565(19)30217-7
doi: 10.1016/j.exger.2019.110663
pii:
doi:

Substances chimiques

Antioxidants 0
Plant Extracts 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

110663

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Mohammed Mukhram Azeemuddin (MM)

Manipal Academy of Higher Education, Manipal, Karnataka, India; R&D Center, The Himalaya Drug Company, Bengaluru, Karnataka, India.

Chamallamudi Mallikarjuna Rao (CM)

Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.

Mohamed Rafiq (M)

R&D Center, The Himalaya Drug Company, Bengaluru, Karnataka, India. Electronic address: dr.rafiq@himalayawellness.com.

Uddagiri Venkanna Babu (UV)

R&D Center, The Himalaya Drug Company, Bengaluru, Karnataka, India.

Paramesh Rangesh (P)

R&D Center, The Himalaya Drug Company, Bengaluru, Karnataka, India.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH